| 朱新华,吕忠英,侯静雯,李秋影,孙明慧.沙库巴曲缬沙坦联合曲美他嗪治疗老年慢性心力衰竭的疗效及相关炎症因子影响[J].,2020,(18):3502-3505 |
| 沙库巴曲缬沙坦联合曲美他嗪治疗老年慢性心力衰竭的疗效及相关炎症因子影响 |
| Efficacy of Shakuba Trvalsartan Combined with Trimetazidine in Elderly Patients with Chronic Heart Failure and the Effects of Related Inflammatory Factors |
| 投稿时间：2020-02-04 修订日期：2020-02-28 |
| DOI：10.13241/j.cnki.pmb.2020.18.023 |
| 中文关键词: 沙库巴曲缬沙坦 曲美他嗪 老年慢性心力衰竭 炎症因子 |
| 英文关键词: Shakuba trvalsartan Trimetazidine Chronic heart failure in the elderly Inflammatory factors |
| 基金项目:新疆维吾尔族自治区自然科学基金项目（2016D01C243） |
|
| 摘要点击次数: 1006 |
| 全文下载次数: 554 |
| 中文摘要: |
| 摘要 目的：探究沙库巴曲缬沙坦联合曲美他嗪治疗老年慢性心力衰竭竭的疗效及相关炎症因子影响。方法：随机选取2018年1月~2019年10月期间在本院接受治疗的60例慢性心力衰竭老年患者，将其随机平分为对照组和研究组，每组各30例，其中对照组在常规治疗的基础上给予沙库巴曲缬沙坦进行治疗，研究组在对照组的基础上给予曲美他嗪进行治疗，两组患者均连续治疗3个月，对比两组治疗总有效率，两组治疗前后的心功能指标，两组治疗前后的炎性因子水平，两组治疗期间的不良反应发生率。结果：研究组的治疗总有效率显著高于对照组(93.33 % vs.76.67 %，P<0.05）。治疗前，两组的左心室收缩末期内径（left ventricular end-systolic diameter, LVESD）、左心室舒张末期内径（left ventricular end-diastolic diameter,LVEDD）、左心室射血分数（left ventricular ejection fraction, LVEF）、血浆N-末端脑钠素前体(N-terminal pro-brain natriuretic peptide，NT-pro BNP)等心功能指标对比均无统计学差异（P>0.05）；治疗后，两组的LVEDD、LVESD、NT-pro BNP指标均比治疗前显著降低，LVEF水平均比治疗前显著升高（P<0.05），且研究组更优（P<0.05）；治疗前，两组的超敏C反应蛋白（high-sensitivity C-reactive protein, hs-CRP）、白介素6（interleukin 6, IL-6）、IL-1、肿瘤坏死因子α（tumor necrosis factor α, TNF-α）等炎性因子水平对比均无统计学差异（P>0.05）；治疗后，两组的上述指标均比治疗前显著降低（P<0.05），且研究组更低（P<0.05）；治疗期间，对照组的不良反应发生率10.0 %（3/30）与研究组13.3 %（4/30）之间无显著性差异（P>0.05）。结论：沙库巴曲缬沙坦联合曲美他嗪治疗老年慢性心力衰竭的效果显著，该方法可有效改善患者的心功能和炎症因子水平，且不良反应未增加，值得临床推广使用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the curative effect of sacurbactra valsartan combined with trimetazidine in elderly patients with chronic heart failure and the influence of related inflammatory factors. Methods: A total of 60 elderly patients with chronic heart failure who were treated in our hospital from January 2018 to October 2019 were randomly selected as research subjects, and they were randomly divided into a control group and an observation group, with 30 cases in each group. Among them, the control group was given Sakuba trvalsartan on the basis of conventional treatment, and the study group was given trimetazidine on the basis of control. The patients in two groups were treated continuously for 3 months. Compare the total effective rate of treatment of the two groups of patients, compare the cardiac function indicators of the two groups of patients before and after treatment, compare the levels of inflammatory factors before and after treatment, and compare the incidence of adverse reactions during the treatment of the two groups of patients. Results: The total effective rate of treatment in the study group was significantly higher than in the control group (93.33 % vs. 76.67 %, P<0.05). Before treatment, there was no significant difference in the LVESD, LVEDD, LVEF, NT-pro BNP and isocardial function in the two groups of patients (P>0.05). After treatment, the LVEDD, LVESD and NT-pro BNP indexes of the two groups of patients were significantly lower than before treatment, the LVEF level was significantly higher than before treatment (P<0.05), and the study group was better (P<0.05). Before treatment, the levels of inflammatory factors such as hs-CRP, IL-6, IL-1 and TNF-α were not statistically different between the two groups (P>0.05). After treatment, the above-mentioned indicators of two groups of patients were significantly lower than before treatment (P<0.05), and the study group was lower (P<0.05). During the treatment period, there was no significant difference in the incidence of adverse reactions between the control group patients at 10.0 % (3/30) and the study group at 13.3 % (4/30) (P>0.05). Conclusion: Sakuba trvalsartan combined with trimetazidine has a significant effect on elderly patients with chronic heart failure. This method can effectively improve the heart function and inflammatory factor levels of patients, and the adverse reactions have not increased. It is worthy of clinical popularization. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
